Description

This grant opportunity from AstraZeneca United States seeks to advance independent medical education focused on addressing practice gaps in the interpretation, communication, and application of HER2 test results in metastatic breast cancer. As HER2 expression in breast cancer is now recognized as a nuanced spectrum, recent clinical advances and updated reporting guidelines have created a need for improved multidisciplinary collaboration and standardized reporting. The grant supports educational initiatives that enhance clinician awareness of the evolving HER2 spectrum, target communication between pathologists, oncologists, and care teams, and promote best practices in HER2 reporting and information flow. Programs may include peer-to-peer case-based discussions, multidisciplinary tumor boards, grand rounds, and local/regional events at community cancer centers.